Home LiteratureArticle Details
PMID: 26071591 Published · ppublish English

Regulation of the Rev1-pol ζ complex during bypass of a DNA interstrand cross-link.

The EMBO journal ·Vol. 34 ·No. 14 ·2015-10-02

Budzowska Magda, Graham Thomas G W, Sobeck Alexandra, Waga Shou, Walter Johannes C

Abstract

DNA interstrand cross-links (ICLs) are repaired in S phase by a complex, multistep mechanism involving translesion DNA polymerases. After replication forks collide with an ICL, the leading strand approaches to within one nucleotide of the ICL ("approach"), a nucleotide is inserted across from the unhooked lesion ("insertion"), and the leading strand is extended beyond the lesion ("extension"). How DNA polymerases bypass the ICL is incompletely understood. Here, we use repair of a site-specific ICL in Xenopus egg extracts to study the mechanism of lesion bypass. Deep sequencing of ICL repair products showed that the approach and extension steps are largely error-free. However, a short mutagenic tract is introduced in the vicinity of the lesion, with a maximum mutation frequency of ~1%. Our data further suggest that approach is performed by a replicative polymerase, while extension involves a complex of Rev1 and DNA polymerase ζ. Rev1-pol ζ recruitment requires the Fanconi anemia core complex but not FancI-FancD2. Our results begin to illuminate how lesion bypass is integrated with chromosomal DNA replication to limit ICL repair-associated mutagenesis.

Keywords
Fanconi anemia genome stability interstrand cross‐link repair translesion synthesis
Article Info
Journal
The EMBO journal
Abbr.
EMBO J
Published
2015-10-02
Indexed
2015-07-16
Updated
2016-10-19
Language
English
Country/Region
England
NLM ID
8208664
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com